<2001³âµµ ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èSymposium - ¾à¹°¿ªÇÐ ¹× ¾à¹°°æÁ¦ÇÐ -
- ÀϽÃ: 2001³â 6¿ù8ÀÏ (±Ý) - Àå¼Ò: ¼¿ï´ëº´¿ø ÀÓ»óÀÇÇבּ¸¼Ò ´ë°´ç
08:30 - 09:00 µî·Ï 09:00 - 09:10 °³È¸»ç ȸÀå Çã°©¹ü <Ư°> ÁÂÀå: ¿¬¼¼ÀÇ´ë Çã°©¹ü 09:10 - 09:40 Trial Simulation ¼¿ïÀÇ´ë ÀåÀÎÁø ÁÂÀå: °¡Å縯ÀÇ´ë ±èÈƱ³ 09:40 - 10:10 PAI-1 »ý¼º¿¡ ´ëÇÑ Adrenal Steroid¿Í Angiotensin IIÀÇ »ó½ÂÀû È¿°ú °¡Å縯ÀÇ´ë ±è°æ¼ö
10:10 - 10:30 ÈÞ½Ä
I ¾à¹°°æÁ¦ÇÐ ÁÂÀå: ¼¿ïÀÇ´ë ½Å»ó±¸ 10:30 - 10:50 ¾à¹°°æÁ¦ÇÐÀÇ °³³ä ÇѾçÀÇ´ë ¹è»óö 10:50 - 11:40 Cost-Effectiveness Analysis Aslam H. Anis 11:40 - 12:00 ±¹³» Study ¿¹ ÇѾçÀÇ´ë À±Çü¶õ 12:00 - 12:10 ÀÓ½ÃÃÑȸ
12:10 - 13:30 Á¡½É½Ä»ç
II ¾à¹°¿ªÇÐ <Ư°> ÁÂÀå: ¿¬¼¼ÀÇ´ë ±è°æȯ 13:30 - 14:20 The Continuum of Postmarketing Drug Surveillance: From Early Signals to Action Andy Stergachis
<ÀÚ¹ßÀû ÀÌ»ó¹ÝÀÀº¸°íü°è> ÁÂÀå: ¼¿ïÀÇ´ë ¹Úº´ÁÖ 14:20 - 14:40 ±¹³»ÇöȲ°ú Á¤ºÎÀÇ °èȹ ½Ä¾àû ÃÖ¼ö¿µ 14:40 - 15:00 º´¿ø³» ÀÌ»ó¹ÝÀÀ ¸ð´ÏÅ͸µ ½Ã¹ü»ç¾÷ ¿¬¼¼ÀÇ´ë 俵¹® 15:00 - 15:20 Á¦¾à¾÷°èÀÇ ÀÔÀå MSD ÀÌ¿ø½Ä 15:20 - 15:40 ¾à¹°¿ªÇÐ ¿¬±¸»ç·Ê Á¦ÁÖÀÇ´ë ¹èÁ¾¸é
15:40 - 16:00 ÈÞ½Ä
<ÀǾàÇ° Àç½É»çÁ¦µµ> ÁÂÀå: ÀÎÇÏÀÇ´ë ³ëÇü±Ù 16:00 - 16:20 Àç½É»çÁ¦µµÀÇ ¹è°æ°ú ¿î¿µ»óȲ ½Ä¾àû È«¼ø¿í 16:20 - 16:40 Àç½É»çÁ¦µµÀÇ ¹®Á¦Á¡°ú °³¼±¹æ¾È ¼¿ïÀÇ´ë ¹Úº´ÁÖ 16:40 - 17:00 Á¦¾à¾÷°èÀÇ ÀÔÀå Çѱ¹Bayer Áöµ¿Çö 17:00 - 17:20 ±¹³» PMS ¿¬±¸»ç·Ê ¿ï»êÀÇ´ë ±è¿µ½Ä 17:20 - 17:40 Åä·Ð ÁÂÀå: ¹Úº´ÁÖ, ³ëÇü±Ù
*°ü·ÃURL : http://www.kscpt.org/HOME/kscpt/kscpt01.nsf/webframe?openframeset
|